PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • ACE inhibitors - Market size and forecast 2018-2023 • ARBs - Market size and forecast 2018-2023 • Other therapeutics - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Introduction of smartphone-based diagnosis and treatment. • Advent of novel therapies • Increasing awareness about renal disorders PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie Inc. • AstraZeneca Plc • Boehringer Ingelheim International GmbH • Bristol-Myers Squibb Co. • Merck & Co., Inc. • Novartis AG • Pfizer Inc. • Sanofi • Takeda Pharmaceutical Co. Ltd. • Teva Pharmaceutical Industries Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: ACE inhibitors - Market size and forecast 2018-2023 ($ millions) Exhibit 21: ACE inhibitors - Year-over-year growth 2019-2023 (%) Exhibit 22: ARBs - Market size and forecast 2018-2023 ($ millions) Exhibit 23: ARBs - Year-over-year growth 2019-2023 (%) Exhibit 24: Other therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Other therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Proportion of geriatric population in Asia 2009 and 2018 (% of the total population) Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in Asia Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Top 3 countries in ROW Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Prevalence/incidence of associated risk factors of proteinuria Exhibit 46: Growth of geriatric population 2009-2018 (%) Exhibit 47: Side effects of ACE inhibitors used for the treatment of proteinuria Exhibit 48: Impact of drivers and challenges Exhibit 49: Vendor landscape Exhibit 50: Landscape disruption Exhibit 51: Vendors covered Exhibit 52: Vendor classification Exhibit 53: Market positioning of vendors Exhibit 54: AbbVie Inc. - Vendor overview Exhibit 55: AbbVie Inc. - Business segments Exhibit 56: AbbVie Inc. - Organizational developments Exhibit 57: AbbVie Inc. - Geographic focus Exhibit 58: AbbVie Inc. - Key offerings Exhibit 59: AbbVie Inc. - Key customers Exhibit 60: AstraZeneca Plc - Vendor overview Exhibit 61: AstraZeneca Plc - Business segments Exhibit 62: AstraZeneca Plc - Organizational developments Exhibit 63: AstraZeneca Plc - Geographic focus Exhibit 64: AstraZeneca Plc - Key offerings Exhibit 65: AstraZeneca Plc - Key customers Exhibit 66: Boehringer Ingelheim International GmbH - Vendor overview Exhibit 67: Boehringer Ingelheim International GmbH - Business segments Exhibit 68: Boehringer Ingelheim International GmbH - Organizational developments Exhibit 69: Boehringer Ingelheim International GmbH - Geographic focus Exhibit 70: Boehringer Ingelheim International GmbH - Segment focus Exhibit 71: Boehringer Ingelheim International GmbH - Key offerings Exhibit 72: Boehringer Ingelheim International GmbH - Key customers Exhibit 73: Bristol-Myers Squibb Co. - Vendor overview Exhibit 74: Bristol-Myers Squibb Co. - Business segments Exhibit 75: Bristol-Myers Squibb Co. - Organizational developments Exhibit 76: Bristol-Myers Squibb Co. - Geographic focus Exhibit 77: Bristol-Myers Squibb Co. - Key offerings Exhibit 78: Bristol-Myers Squibb Co. - Key customers Exhibit 79: Merck & Co. Inc. - Vendor overview Exhibit 80: Merck & Co. Inc. - Business segments Exhibit 81: Merck & Co. Inc. - Organizational developments Exhibit 82: Merck & Co. Inc. - Geographic focus Exhibit 83: Merck & Co. Inc. - Segment focus Exhibit 84: Merck & Co. Inc. - Key offerings Exhibit 85: Merck & Co. Inc. - Key customers Exhibit 86: Novartis AG - Vendor overview Exhibit 87: Novartis AG - Business segments Exhibit 88: Novartis AG - Organizational developments Exhibit 89: Novartis AG - Geographic focus Exhibit 90: Novartis AG - Segment focus Exhibit 91: Novartis AG - Key offerings Exhibit 92: Novartis AG - Key customers Exhibit 93: Pfizer Inc. - Vendor overview Exhibit 94: Pfizer Inc. - Business segments Exhibit 95: Pfizer Inc. - Organizational developments Exhibit 96: Pfizer Inc. - Geographic focus Exhibit 97: Pfizer Inc. - Segment focus Exhibit 98: Pfizer Inc. - Key offerings Exhibit 99: Pfizer Inc. - Key customers Exhibit 100: Sanofi - Vendor overview Exhibit 101: Sanofi - Business segments Exhibit 102: Sanofi - Organizational developments Exhibit 103: Sanofi - Geographic focus Exhibit 104: Sanofi - Segment focus Exhibit 105: Sanofi - Key offerings Exhibit 106: Sanofi - Key customers Exhibit 107: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 108: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 113: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 114: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 115: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 116: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 117: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 118: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 119: Validation techniques employed for market sizing Exhibit 120: Definition of market positioning of vendors

AbbVie Inc. AstraZeneca Plc Boehringer Ingelheim International GmbH Bristol-Myers Squibb Co. Merck & Co. Inc. Novartis AG Pfizer Inc. Sanofi Takeda Pharmaceutical Co. Ltd. Teva Pharmaceutical Industries Ltd.